Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial

IMPORTANCE: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). OBJECTI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Neurol
Main Authors: Healey, Jeff S., Gladstone, David J., Swaminathan, Balakumar, Eckstein, Jens, Mundl, Hardi, Epstein, Andrew E., Haeusler, Karl Georg, Mikulik, Robert, Kasner, Scott E., Toni, Danilo, Arauz, Antonio, Ntaios, George, Hankey, Graeme J., Perera, Kanjana, Pagola, Jorge, Shuaib, Ashfaq, Lutsep, Helmi, Yang, Xiaomeng, Uchiyama, Shinichiro, Endres, Matthias, Coutts, Shelagh B., Karliński, Michal, Czlonkowska, Anna, Molina, Carlos A., Santo, Gustavo, Berkowitz, Scott D., Hart, Robert G., Connolly, Stuart J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583060/
https://ncbi.nlm.nih.gov/pubmed/30958508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.0617
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados